Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.Blood · 2020
   Trial
2. Management of relapsed/refractory AL amyloidosis.Blood advances · 2026
   Review
3. Serum free light chain level-based and non-fixed cycle daratumumab treatment strategy for patients with light chain amyloidosis.Annals of medicine · 2025
   Article
4. Renal AL Amyloidosis: Updates on Diagnosis, Staging, and Management.Journal of clinical medicine · 2024
   Review
5. Diagnosis and Treatment of AL Amyloidosis.Drugs · 2023
   Review
6. COVID-19 Exposure Unmasking Systemic Amyloidosis With Hepatic Predominance.Cureus · 2022
   Article
7. Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis.Hemato · 2021
   Article
8. Hepatic AL Amyloidosis without Significant Light Chain Elevation in a Patient Treated with CyBorD Plus Daratumumab.The American journal of case reports · 2021
   Article
9. Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management.HemaSphere · 2020
   Review
10. Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic.British journal of haematology · 2020
    Review
11. New developments in diagnosis, risk assessment and management in systemic amyloidosis.Blood reviews · 2020
    Review
12. Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives.Journal of blood medicine · 2019
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as